Musunuru provided ESGCT delegates with promising news of a roadmap following the diagnosis and treatment of Baby KJ.
In April 2025, AstraZeneca announced that its experimental oral PCSK9 inhibitor, AZD0780, achieved a 50.7% reduction in LDL ...
As industry leaders gather at the annual event in Phoenix, the cell and gene therapy space remains in a state of flux, with M ...
CRISPR therapies offer precise gene-editing solutions for treating genetic disorders and other complex diseases. Rising prevalence of genetic conditions drives adoption, and emerging CRISPR-based ...
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with ...
Zacks Investment Research on MSN
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and ...
Wonderful. Thank you, guys. It is wonderful to see you all here today. Thank you so much for taking the time. It is my privilege to have the Viking team here with me. I've got Gregory and Brian, CEO ...
Palvella’s QTORIN rapamycin is its main value driver. This candidate is in Phase 3 trials for mLM. Management anticipates its top-line data by Q1 2026, with a potential NDA planned by 2H2026. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback